- About Us
- Our Science
- Investors & Media
- Aurinia Gives
- Contact Us
AUR300 is a novel peptide therapeutic that modulates M2 macrophages (a type of white blood cell) via the macrophage mannose receptor CD206. Dysregulation of M2 macrophages drives fibrosis. Unlike AUR200 and VCS, which target B-cell and T-cell activity of the adaptive immune response, AUR300 targets the innate part of the immune system, specifically M2 macrophages. There is growing recognition that the innate immune system plays a more prominent role in autoimmune disease pathogenesis than may have been previously appreciated. AUR300 acts to reduce M2 dysregulation and decrease inflammatory cytokines and therefore may have significant clinical applications for autoimmune and fibrotic diseases.
AUR300 has a proven mechanism of action.
We anticipate that an IND for AUR300 will be submitted in 2024.